Bristol-Myers Squibb (US.BMY)
Capital Allocation Audit · Period: 2010 – 2026
Key Metrics
US.BMY · YoY: 2026 H1 vs 2025 H1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 85.5% | → |
| ROE | 26.9% | ↑ |
| Cash Conversion | 75.0% | ↓ |
| D/E Ratio | 2.02 | ↑ |
| Gross Margin | 70.8% | → |
US.BMY (Bristol-Myers Squibb) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY --------------------------- FCF Conversion 85.5% → ROE 26.9% ↑ Cash Conversion 75.0% ↓ D/E Ratio 2.02 ↑ Gross Margin 70.8% →
Key Metrics
US.BMY (Bristol-Myers Squibb) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY---------------------------FCF Conversion 85.5% →ROE 26.9% ↑Cash Conversion 75.0% ↓D/E Ratio 2.02 ↑Gross Margin 70.8% →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies